ADARx Pharmaceuticals, Inc. (ADRX): who owns it and who trades it
As of Nov 13, 2026, ADRX insiders reported 5 purchases worth $33.3M in the last 12 months. The largest buyer was Sr One Capital Management, Llc (10% owner), with $17.1M.
Latest filing Nov 13, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, ADRX insiders reported $33.3M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Erez Chimovits | Director | Purchase | 61,516 | $17.00 | $1M | Form 4 |
| Sep 28, 2026 | Carl L Gordon | Director | Purchase | 300,249 | $17.00 | $5.1M | Form 4 |
| Sep 28, 2026 | Carl L Gordon | Director | Purchase | 588,235 | $17.00 | $10M | Form 4 |
| Sep 28, 2026 | Sr One Capital Management, Llc | 10% owner | Purchase | 414,814 | $17.00 | $7.1M | Form 4 |
| Sep 28, 2026 | Sr One Capital Management, Llc | 10% owner | Purchase | 592,593 | $17.00 | $10.1M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sr One Capital Management, Llc | 10% owner | $17.1M | – | Sep 28, 2026 |
| Carl L Gordon | Director, 10% owner | $15.1M | – | Sep 28, 2026 |
| Erez Chimovits | Director | $1M | – | Sep 28, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ADRX short interest
1.80M ADRX shares are sold short. Over the last 3 reports the number of shares short went up 55%.
As of Oct 30, 2026, 1.80M ADRX shares were sold short, down 5.4% from the report before. At the average daily volume of 358,545 shares, buying them all back would take about 5.0 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.80M | – | -5% | 358,545 | 5.0 |
| Oct 15, 2026 | 1.90M | – | +64% | 611,710 | 3.1 |
| Sep 30, 2026 | 1.16M | – | – | 669,771 | 1.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
ADARx Pharmaceuticals company events
ADARx Pharmaceuticals filed 1 report on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 28, 2026.
- Sep 28, 2026AnnouncementThe Company closed the IPO of 26,250,000 shares of Common Stock at a price to the public of $17.00 per share. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named ADRX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Zhen Li | 13G | 9.7% |
| Nov 13, 2026 | Zhen Li | 13G | 9.7% |
| Oct 16, 2026 | LAV Biosciences Fund V, L.P. | 13G | 10.5% |
| Oct 16, 2026 | LAV Biosciences Fund V, L.P. | 13G | 10.5% |
| Oct 5, 2026 | SR One Capital Management, LLC | 13D | 9.3% |
| Oct 5, 2026 | SR One Capital Management, LLC | 13D | 9.3% |
| Oct 2, 2026 | ORBIMED ADVISORS LLC | 13D | 14.0% |
| Oct 2, 2026 | ORBIMED ADVISORS LLC | 13D | 14.0% |
| Oct 1, 2026 | BCLS Fund III Investments, LP | 13G | 6.3% |
| Oct 1, 2026 | BCLS Fund III Investments, LP | 13G | 6.3% |
Questions about ADARx Pharmaceuticals, Inc. (ADRX) stock
Are ADRX insiders buying or selling?
In the last 12 months, ADRX insiders reported 5 open-market purchases worth $33.3M and no sales. The latest trade was on Sep 28, 2026. See every trade.
What is the short interest in ADRX?
As of Oct 30, 2026, 1.80M ADRX shares were sold short, down 5.4% from the report before. At the average daily volume of 358,545 shares, buying them all back would take about 5.0 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.